Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity
of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic
triple negative breast cancer (TNBC) who have not received prior systemic therapy for
metastatic breast cancer (mBC).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai Jiaolian Drug Research and Development Co., Ltd